The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
about
Testosterone Replacement Therapy and Prostate Cancer IncidenceTestosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic riskLow serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancerEndogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?Novel diagnostic biomarkers for prostate cancer.Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.The role of testosterone in the pathogenesis of prostate cancer.Testosterone therapy and prostate cancer.Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.Circulating steroid hormones in prostate carcinogenesis. Part 1 - Androgens.Testosterone Therapy Among Prostate Cancer Survivors.Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer.Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy resultHigher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy.The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy.Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.A novel model to predict positive prostate biopsy based on serum androgen level.Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
P2860
Q26771774-EC6E94E3-09FF-45A6-820D-B17CF0B53DD8Q26775766-169D2D97-2CEF-4478-B888-B4F0DB7CDCF0Q33599365-A27BFC34-A5C2-49B3-9BBC-F262853C9D09Q33890197-855DDF6A-E16D-40EA-B262-9913BD9A3DB2Q34231678-58018335-951F-4F70-9A91-D714A528D1A1Q34468676-C890C170-42C1-42E6-A82B-B0E03D03E1F3Q36304676-AABB015C-E759-4EC2-813F-77F0BB8F4702Q37145218-9CA32030-7980-47AA-821E-B968ECF95385Q37531045-F16202D0-5416-443E-AB87-3D350FA7E4BEQ37605856-C2CE941C-1940-479D-9CF7-CD20490B9881Q38471454-D3F0AE6D-A978-491B-92E2-256B16A24BB4Q38913362-AA1D8A70-65CE-4ED1-A6C2-32CDFEF60A57Q39105066-BB063539-1F3B-4452-8405-F74B2F839349Q39483117-FE7C2C4D-849E-40A0-8745-52EAA984D83EQ40076743-EF9C2D37-0344-49B6-837B-E1E3D5F9F19AQ40289446-EE5B42F3-0506-4B34-ACB7-92D4D212E8D4Q40485378-0783AC46-5832-4C31-9314-0BFAB5291214Q41836862-B2FF1945-226B-44CB-9CF2-B6888624600FQ46158562-FC963B57-9FDB-456C-BDF4-E6030315A3C8Q46561665-C7AF7753-2EF5-4FDC-9A22-BDCFDB2BC15AQ46682568-1FE68088-F9C8-421A-96D5-9590E2086D8CQ47127295-36C07279-8BE1-451F-BDF3-44FC6767FDD2Q47137331-7CB6BB50-6CF0-4ABB-9D38-FFD33ABD20EDQ48573622-D8B3B17C-484F-4117-ADE8-4F6A3C1F3B1AQ48743405-9B31F3DE-7CEB-4E67-A32E-87FBD3FFD940Q52996349-29A0C520-6B1A-4354-92E3-C277D4BADF5A
P2860
The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The clinical potential of pret ...... of prostate cancer screening.
@en
The clinical potential of pret ...... of prostate cancer screening.
@nl
type
label
The clinical potential of pret ...... of prostate cancer screening.
@en
The clinical potential of pret ...... of prostate cancer screening.
@nl
prefLabel
The clinical potential of pret ...... of prostate cancer screening.
@en
The clinical potential of pret ...... of prostate cancer screening.
@nl
P2093
P1433
P1476
The clinical potential of pret ...... of prostate cancer screening.
@en
P2093
Akira Komiya
Hiroyoshi Suzuki
Masashi Yano
Satoko Kojima
Satoshi Fukasawa
Takashi Imamoto
Tomohiko Ichikawa
Yukio Naya
P304
P356
10.1016/J.EURURO.2006.08.047
P407
P577
2006-09-12T00:00:00Z